MTCM
NKGN

Mint Tower Capital Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Mint Tower Capital Management’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-200,000
Closed -$1.66M – 258
2023
Q3 		$1.66M Hold
200,000
– – 0.27% 84
2023
Q2 		$2.07M Hold
200,000
– – 0.2% 74
2023
Q1 		$2.03M Hold
200,000
– – 0.21% 66
2022
Q4 		$1.99M Buy
+200,000
New +$1.98M 0.18% 106

Other funds holding NKGN

SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
UOC
University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Mint Tower Capital Management's NKGN Position: Q4 2023 in Review

Mint Tower Capital Management sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2023, closing a stake of 200,000 shares — an estimated $1.66M sold.

Mint Tower Capital Management first reported a position in NKGN in Q4 2022 and held it in 4 quarters. The position peaked at $2.07M in Q2 2023. 9 funds tracked by Wall St. Rank hold NKGN as of Q4 2023.

  • Mint Tower Capital Management reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Mint Tower Capital Management sold 200,000 NKGen Biotech, Inc. Common Stock shares in Q4 2023, an estimated $1.66M.
  • Mint Tower Capital Management first reported a position in NKGen Biotech, Inc. Common Stock in Q4 2022 and held it in 4 quarters.
  • Mint Tower Capital Management's NKGen Biotech, Inc. Common Stock position peaked at $2.07M in Q2 2023.
  • 9 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2023.

Based on Mint Tower Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.